Glenmark launches generic Bumex

Glenmark is debuting bumetanide injection, 1 mg/4 ml (0.25 mg/ml) single-dose vials and 2.5 mg/10 ml (0.25 mg/ml) multi-dose vials, the generic version of Validus’ Bumex.

Bumex is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease and kidney disease.

[Read more: Glenmark expands OTC portfolio with acquisition of Wockhardt’s ANDAs]

“We are very pleased to bring to market a lower cost alternative to Bumex injection, 0.25 mg/ml. This launch of bumetanide injection, 1 mg/4 ml (0.25 mg/ml) single-dose vials and 2.5 mg/10 ml (0.25 mg/ml) multi-dose vials affirms our commitment to Glenmark’s continued focus on institutional business,” said Vijay Raghavan, senior vice president, business development portfolio, product launch and strategy at Glenmark.

Bumex had a market value of roughly $16.5 million for the 12-month period ending November 2022, according to IQVIA.